组蛋白去乙酰化酶抑制剂诱导肿瘤细胞凋亡的机制

组蛋白去乙酰化酶抑制剂（HDACi）是一类新的化疗药物,能够有效抑制组蛋白去乙酰化酶的活性,促进组蛋白及非组蛋白的乙酰化修饰,在转录和翻译后修饰水平调控肿瘤靶蛋白及凋亡相关蛋白的表达和降解,活化凋亡信号通路,诱导肿瘤细胞凋亡。HDACi抑制抗氧化蛋白的表达,提高细胞内活性氧的水平,引起细胞的氧化损伤。因此,氧化损伤诱导的细胞凋亡也是HDACi杀伤肿瘤细胞的重要机制。HDACi诱导细胞凋亡机制的发现将进一步促进HDACi在临床治疗中的应用。     

细胞命运转化中的染色质重塑及其表观遗传调控机制

染色质重塑是重要的表观遗传调控机制,参与调控许多重要生物过程,但细胞命运转化中染色质变化模式及其调控机制并不清楚。围绕这一问题,江赐忠和高绍荣实验室研究了小鼠体细胞重编程及人胚胎干细胞(ESC)定向分化成神经外胚层细胞(NEC)中染色质重塑及其作用机制,取得一系列前沿性进展:揭示体细胞重编程中发生精确的核小体重塑,使之获得与ESC没有差别的染色质结构;绘制体细胞重编程中核心全能性转录因子Oct4的动态结合靶点与关键组蛋白修饰变化的分子路线图,及其两者互作对全能性获得与维持的调控机制;发现人ESC向NEC分化中,紧挨转录起始位点上游的核小体缺失区发生核小体丢失,激活NEC相关基因,组蛋白乙酰基转移酶KAT2B增加H3K9ac信号来招募转录因子Sox2结合到NEC特异靶点激活靶点基因,促进NEC分化。这些成果极大提高人们对细胞命运转化中染色质重塑及其表观遗传调控机制的认识。     

microRNAs和体细胞重编程

体细胞重编程与microRNAs(miRNAs)均为近年来研究的热点问题。到目前为止,能成功诱导体细胞形成多能性干细胞的体细胞重编程方法有核移植(nuclear transfer,NT)和外源因子诱导形成多能干细胞(induced pluripotent stem cells,iPSc)两种,这两种方法让人们看到了体细胞重编程在细胞治疗方面具有诱人的应用前景。miRNAs是真核生物中存在的一类长度为22nt左右起调控作用的内源性非编码RNA,它在转录后水平调节靶基因的表达,是细胞内基因表达的基本调控机制之一。近年的研究结果表明,miRNAs在干细胞干性维持和分化过程中具有重要的调节作用,从miRNAs角度研究体细胞重编程机理将对体细胞重编程的应用具有重要意义。     

组蛋白去乙酰化酶抑制剂的研究进展

核小体是真核生物染色质的基本单位,通过对组蛋白核心的N-端的乙酰化、甲基化、磷酸化、遍在蛋白化的修饰作用而影响细胞的功能。组蛋白乙酰化酶(histone acetylase HAT)及组蛋白去乙酰化酶(Histone Deacetylases HDAC)之间的动态平衡控制着染色质的结构和基因表达。当组蛋白去乙酰化水平增加,乙酰化水平相对降低,即会导致正常的细胞周期与代谢行为的改变而诱发肿瘤,及神经退行性变。组蛋白去乙酰化酶抑制剂(Histone Deacetylases-inhibitor HDACi)目前是国内外研究的热点。其中,曲古霉素A(Trichostatin A TSA),是最早发现的天然组蛋白去乙酰化酶抑制剂;伏立诺他(Suberoylanilide Hydroxamic Acid SAHA)已经美国FDA批准用于治疗皮肤T细胞淋巴瘤。本文就HDACi分类及其功能出发综述HDACi的作用机制及研究进展。     

哺乳动物DNA甲基化及其在体细胞诱导重编程中的作用

诱导多能干细胞(Induced pluripotent stem cell, iPS)技术提供了将终末分化的细胞逆转为多潜能干细胞的可能, 在干细胞基础理论研究和再生医学中具有重要意义。然而, 目前体细胞诱导重编程方法效率极低, 常发生不完全的重编程。研究表明, 在不完全重编程的细胞中存在体细胞的表观遗传记忆, 而DNA甲基化作为相对长期和稳定的表观遗传修饰, 是影响重编程效率和iPS细胞分化能力的重要因素之一。哺乳动物DNA甲基化是指胞嘧啶第五位碳原子上的甲基化修饰, 常发生于CpG位点。DNA甲基化能够调节体细胞特异基因和多能性基因的表达, 因此其在哺乳动物基因调控、胚胎发育和细胞重编程过程中发挥着重要作用。此外, 异常DNA甲基化可能导致iPS细胞基因印记的异常和X染色体的失活。文章重点围绕DNA甲基化的机制、分布特点、及其在体细胞诱导重编程中的作用进行了综述。     

钙离子通道亚基Cacnb3对小鼠脂肪间充质干细胞成骨分化的促进作用

间充质干细胞在治疗骨相关疾病中具有重要意义,但其在成骨分化中的机制尚未完全阐明。该研究通过分析GEO数据库中有关组蛋白去乙酰化酶抑制剂(HDACi)处理过的小鼠成骨前体细胞(MC3T3-E1 preosteoblasts)的生物芯片数据,筛选出22个在成骨分化中上调,在成脂分化中下调,且受HDACi紧密调控的基因。这22个基因中有6个基因(Cacnb3、Lpcat2、Cd248等)与Ca~(2+)调节功能相关,提示Ca~(2+)可能在MSCs分化中发挥重要作用。在后续实验中,我们观察到电压依赖性钙通道亚单位β3(calcium voltage-gated channel auxiliary subunit beta 3, Cacnb3)和磷脂酰基转移酶2(lysophosphatidylcholine acyltransferase 2, Lpcat2)在小鼠脂肪间充质干细胞(ADSCs)、人骨髓间充质干细胞(hBMSCs)和小鼠成骨前体细胞(MC3T3-E1)的成骨分化过程中上调,提示Cacnb3、Lpcat2可能参与ADSCs的体外成骨分化。此外,利用钙离子荧光探针检测方法,发现敲低Cacnb3后3T3-E1细胞内Ca~(2+)浓度明显低于对照组,同时,成骨相关基因(ALP、Runx2)表达显著下调,表明Cacnb3可能通过影响Ca~(2+)浓度调控细胞的成骨分化,该研究为进一步探索间充质干细胞成骨分化的机制奠定了基础。     

外遗调节与神经干细胞分化

神经发生与神经干细胞的分化调控机制是当今神经发育生物学的重要研究热点,在阐明干细胞的可塑性机制和临床治疗神经退行性疾病等方面具有广阔的应用前景。最近研究表明,外遗调节在神经干细胞的生长及分化方面表现出重要作用。这些外遗调节包括组蛋白的乙酰化/去乙酰化,DNA甲基化以及非编码RNAs对细胞命运决定的影响。     

组蛋白去甲基化酶在发育和再生医学的研究

表观遗传学调控在器官发育以及再生医学中是重要的研究内容,而组蛋白的甲基化修饰属于表观遗传学调控机制之一并且成为近年来研究的热点内容。处于不同甲基化状态下的组蛋白,能影响多种分子对其的识别和结合,在转录起始、转录效率和转录后加工等多个层面调控相关基因的表达。而哺乳动物的器官发育与细胞重编程都与基因选择性表达密切相关,因此组蛋白甲基化状态在基因选择性表达中扮演着重要角色。本文概述了组蛋白去甲基化酶的分类以及组蛋白不同甲基化状态下对于基因的表达的调控,同时总结了组蛋白去甲基化酶在维持胚胎干细胞的多分化潜能和IPS细胞重编程效率方面的作用以及组蛋白去甲基化酶基因的缺失与相关器官发育的影响。最后探讨了组蛋白甲基化修饰酶在推动发育生物学与再生医学研究进展方面的潜能。     

胚胎干细胞及诱导多能干细胞向心肌细胞分化和调控的研究进展

胚胎干细胞（embryonic stem cells,ESCs）具有自我更新、无限增殖和多向分化的特性,包括分化成心脏组织的多种类型细胞。经体细胞重编程产生的诱导多能干细胞（induced pluripotent stem cells,iPS）也被证明有类似胚胎干细胞的特性。但这些多能干细胞向心肌细胞自发分化的效率非常低,因此,如何有效地诱导这些多能干细胞向心肌细胞的定向分化对深入认识心肌发生发育的关键调控机制和实现其在药物发现和再生医学,如心肌梗塞、心力衰竭的细胞治疗以及心肌组织工程中的应用均具有非常重要的意义。该文重点综述了近年来胚胎干细胞及诱导多能干细胞向心肌细胞分化和调控的研究进展,并探讨了这一研究领域亟待解决的关键问题和这些多能干细胞的应用前景。     

诱导重编程的表观遗传调控研究进展

表观遗传调控是细胞命运变化与决定的重要基础之一。2006年,日本科学家山中伸弥发现通过4个转录因子Oct4、Sox2、Klf4和c-Myc可以将已经分化的体细胞逆转回与胚胎干细胞相似的多能性状态,获得诱导多能干细胞(induced pluripotent stem cells,i PSCs)。这种诱导重编程技术不仅是干细胞技术的一大突破,也提供了关键的体外模型用于研究细胞重编程的表观遗传机制。对该机制的深入理解将推动人类自由操纵细胞命运的进程,从而有望治疗各种因功能细胞、组织、器官缺失退化引发的疾病。从诱导重编程的表观遗传调控方向的研究进展出发,阐述通过诱导重编程发现的关键细胞命运转变表观调控机制,展望未来的主要研究目标。     

A Combined Epigenetic and Non-Genetic Approach for Reprogramming Human Somatic Cells

Reprogramming of somatic cells to different extents has been reported using different methods. However, this is normally accompanied by the use of exogenous materials, and the overall reprogramming efficiency has been low. Chemicals and small molecules have been used to improve the reprogramming process during somatic cell nuclear transfer (SCNT) and induced pluripotent stem (iPS) cell generation. We report here the first application of a combined epigenetic and non-genetic approach for reprogramming somatic cells, i.e., DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors, and human embryonic stem cell (hESC) extracts. When somatic cells were pretreated with these inhibitors before exposure to hESC (MEL1) extracts, morphological analysis revealed a higher rate of hESC-like colony formation than without pretreatment. Quantitative PCR (qPCR) demonstrated that pluripotency genes were upregulated when compared to those of somatic cells or treated with hESC extracts alone. Overall changes in methylation and acetylation levels of pretreated somatic cells suggests that epigenetic states of the cells have an effect on reprogramming efficiency induced by hESC extracts. KnockOutserum replacement (KOSR™) medium (KO-SR) played a positive role in inducing expression of the pluripotency genes. hESC extracts could be an alternative approach to reprogram somatic cells without introducing exogenous materials. The epigenetic pre-treatment of somatic cells could be used to improve the efficiency of reprogramming process. Under differentiation conditions, the reprogrammed cells exhibited differentiation ability into neurons suggesting that, although fully reprogramming was not achieved, the cells could be transdifferentiated after reprogramming.     

Oxamflatin significantly improves nuclear reprogramming, blastocyst quality, and in vitro development of bovine SCNT embryos

Aberrant epigenetic nuclear reprogramming results in low somatic cloning efficiency. Altering epigenetic status by applying histone deacetylase inhibitors (HDACi) enhances developmental potential of somatic cell nuclear transfer (SCNT) embryos. The present study was carried out to examine the effects of Oxamflatin, a novel HDACi, on the nuclear reprogramming and development of bovine SCNT embryos in vitro. We found that Oxamflatin modified the acetylation status on H3K9 and H3K18, increased total and inner cell mass (ICM) cell numbers and the ratio of ICM∶trophectoderm (TE) cells, reduced the rate of apoptosis in SCNT blastocysts, and significantly enhanced the development of bovine SCNT embryos in vitro. Furthermore, Oxamflatin treatment suppressed expression of the pro-apoptotic gene Bax and stimulated expression of the anti-apoptotic gene Bcl-XL and the pluripotency-related genes OCT4 and SOX2 in SCNT blastocysts. Additionally, the treatment also reduced the DNA methylation level of satellite I in SCNT blastocysts. In conclusion, Oxamflatin modifies epigenetic status and gene expression, increases blastocyst quality, and subsequently enhances the nuclear reprogramming and developmental potential of SCNT embryos.     

An HDAC2-TET1 switch at distinct chromatin regions significantly promotes the maturation of pre-iPS to iPS cells

The maturation of induced pluripotent stem cells (iPS) is one of the limiting steps of somatic cell reprogramming, but the underlying mechanism is largely unknown. Here, we reported that knockdown of histone deacetylase 2 (HDAC2) specifically promoted the maturation of iPS cells. Further studies showed that HDAC2 knockdown significantly increased histone acetylation, facilitated TET1 binding and DNA demethylation at the promoters of iPS cell maturation-related genes during the transition of pre-iPS cells to a fully reprogrammed state. We also found that HDAC2 competed with TET1 in the binding of the RbAp46 protein at the promoters of maturation genes and knockdown of TET1 markedly prevented the activation of these genes. Collectively, our data not only demonstrated a novel intrinsic mechanism that the HDAC2-TET1 switch critically regulates iPS cell maturation, but also revealed an underlying mechanism of the interplay between histone acetylation and DNA demethylation in gene regulation.     

The Epigenetic Reprogramming Roadmap in Generation of iPSCs from Somatic Cells

Reprogramming of somatic cells to induced pluripotent stem cells(iPSCs) is a comprehensive epigenetic process involving genome-wide modifications of histones and DNA methylation. This process is often incomplete, which subsequently affects i PSC reprograming,pluripotency, and differentiation capacity. Here, we review the epigenetic changes with a focus on histone modification(methylation and acetylation) and DNA modification(methylation) during i PSC induction. We look at changes in specific epigenetic signatures, aberrations and epigenetic memory during reprogramming and small molecules influencing the epigenetic reprogramming of somatic cells. Finally,we discuss how to improve i PSC generation and pluripotency through epigenetic manipulations.     

Comparison of potency between histone deacetylase inhibitors trichostatin A and valproic acid on enhancing in vitro development of porcine somatic cell nuclear transfer embryos

Epigenetic modification influences reprogramming and subsequent development of somatic cell nuclear transfer (SCNT) embryos. Such modification includes an increase in histone acetylation. Histone deacetylase inhibitors (HDACi), such as trichostatin A (TSA) and valproic acid (VPA), have been known to maintain a high cellular level of histone acetylation. Hence, treatment of nuclear transfer embryos with HDACi may increase the efficiency of cloning. The present study attempted direct comparison of TSA and VPA with regard to the potency of enhancement of in vitro development in porcine SCNT embryos. Reconstructed oocytes using fetal fibroblasts were cultured in PZM-3 containing no HDACi (control), 5 mM VPA, or 50 nM TSA for 24 h, and another 5 d thereafter without HDACi. The frequency of blastocyst formation was significantly higher (P<0.05) in embryos treated with VPA than the frequencies with TSA and without HDACi (125/306, 40.8% vs. 94/313, 30.2% vs. 80/329, 23.4%). In addition, VPA treatment significantly increased (P<0.05) the number of inner cell mass (ICM) cells compared with the control (15.6 ± 1.7 vs. 10.8 ± 2.6), whereas no differences were observed between the TSA treatment and control groups (12.9 ± 3.0 vs. 10.8 ± 2.6). The present study demonstrates that VPA enhances in vitro development of porcine SCNT embryos, particularly by an increase in blastocyst formation and in the number of ICM cells, suggesting that VPA may be more potent than TSA in supporting developmental competence of cloned embryos.